The impact of dispensing fees on compliance with opioid substitution therapy: a mixed methods study by unknown
Shepherd et al. Substance Abuse Treatment, Prevention, and Policy 2014, 9:32
http://www.substanceabusepolicy.com/content/9/1/32RESEARCH Open AccessThe impact of dispensing fees on compliance
with opioid substitution therapy: a mixed
methods study
Alexandra Shepherd, Bianca Perrella and Hendrika Laetitia Hattingh*Abstract
Background: Opioid substitution therapy (OST) programs involve the dispensing of OST medicines to patients to
address their dependence on heroin and/or other opioid substances. OST medicines are subsidised by the
Australian government but patients need to pay the dispensing fees. This study explored opinions from OST
patients and stakeholders about the potential impact of dispensing fees on compliance and OST program
retention. Current and past experiences and the potential impact of OST dispensing fees were evaluated.
Methods: Mixed methodology was used to obtain data from OST patients and stakeholders. This involved
1) interviews with OST stakeholders, 2) a focus group of OST patients and 3) surveys of OST patients in Perth,
Australia, between June and August 2013.
Results: The majority of the eight stakeholders declared cost as the factor mostly impacting on OST compliance.
Almost all of the stakeholders commented that there was a positive correlation between time on the OST program
and success in terms of relapse. Most stakeholders advocated for OST fees to contribute towards the
Pharmaceutical Benefits Scheme Safety Net, and for fee subsidy. Focus group themes supported stakeholder
interview findings. A total of 138 surveys were completed. Survey analysis illustrated a strong correlation between
patient debt and impacted lifestyle: 82.4% (p < 0.001, Chi-square test) of the 138 survey participants stated that
dispensing fees impacted significantly on patients’ finances and lifestyle, specifically those patients with major debt.
The cost of dispensing fees was identified by 46.3% (64/138) of survey participants as the biggest impacting factor
on patient success. Logistic regression models showed that the cost of dispensing fees was also found to
significantly influence both the occurrence of debt (57.7%, p < 0.0001) and lifestyle difficulties (80.0%, p = 0.0004).
Conclusion: Findings provided insight into OST patients’ financial difficulties with data suggesting that dispensing
fees are likely to have a negative impact on OST patients’ compliance with therapy, retention in the OST program
and lifestyle. Government sponsorship of the OST dispensing fees should be considered as sponsorship would
potentially increase the retention rates of income-poor OST program recipients.Introduction
Opioid substitution therapy (OST) programs are suc-
cessful at addressing dependence on heroin and other
opioid substances [1,2]. These programs involve the as-
sessment and treatment of people with an opioid addic-
tion and the dispensing of OST medicines to address
their dependence on heroin and/or other opioid sub-
stances. This, in turn, reduces the negative behaviours,
health issues, physiological issues and crime associated* Correspondence: l.hattingh@curtin.edu.au
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unless otherwise stated.with opioid misuse [3,4]. OST has been proven cost-
effective [2,5,6] for governments due to the reduction of
illicit drug use costs to the health system [1,7,8] and de-
creased crime rate and other indirect costs to society
[9,10]. The primary aim of OST is for patients to de-
crease and eventually cease their opioid misuse and im-
prove their quality of life [11]. The positive outcomes
observed from OST include decreased risk of injecting
infections, illnesses and fatalities [9,12] and increased
ability to perform daily tasks as compared to when using
illicit heroin [4].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Shepherd et al. Substance Abuse Treatment, Prevention, and Policy 2014, 9:32 Page 2 of 9
http://www.substanceabusepolicy.com/content/9/1/32There are three OST medicines available in Australia
and all three should be administered at a pharmacy
under a pharmacist’s supervision, unless take-away doses
have been authorised. The most commonly used medi-
cine is methadone which needs to be taken daily. Bupre-
norphine (branded as Subutex®) and buprenorphine with
naloxone (branded as Suboxone®) have varied dosing re-
quirements with frequency ranging between daily to
every third day [13]. All three OST medicines are subsi-
dised by the Australian government through Section 100
of the National Health Act 1953 (Cth) and are included
in the Pharmaceutical Benefits Scheme (PBS) [14,15].
However, the dispensing fees associated with supplying
the medicines have to be paid by patients and do not
contribute towards the Safety Net Scheme [12,16], which
is a scheme that provides financial assistance to patients
with substantial pharmaceutical expenses [17]. There is
no set dispensing fee charged to OST patients and there
are large price disparities across community pharmacies
in the various Australian jurisdictions [12]. Previous re-
search indicated that OST fees ranged between $18 and
$56 per week [18].
Various approaches need to be followed in the man-
agement of opioid addiction and there are many vari-
ables that may affect a patient’s success and retention on
the OST program. Although financial support towards
dispensing fees is only one aspect to encourage patients
to be treated and be retained in care financial instability
is one concern that is frequently raised [10,18,19]. The
demographic of patients on OST is generally in the
lower income bracket and it was estimated in 2005 that
only 17% of Australian OST patients received their main
income from paid work [20]. Income from government
support has, however, been reported to be insufficient
for patients to buy groceries with some patients having
to prioritise their OST fees over buying food on certain
occasions [15]. It has also been found that large numbers
of patients have acquired significant debt to pharmacies
to cover the dispensing fees [12,21-24].
A 2008 Australian study involving 508 OST patients
found that 23% of the patients owed money to pharma-
cies and 32% of the patients could not afford the dis-
pensing fees, which resulted in some patients missing
their dose(s) [18]. This study also indicated that patients
were not satisfied with the dosing hours, number of
venues available to dose, and not having enough take-
away doses [18]. A study conducted in the United States
of America (USA) evaluated the retention rates of pa-
tients on OST within two states after OST treatment
subsidisation by Medicaid was introduced [19]. The re-
tention rates increased from 28% to 51% in one state
and from 28% to 34% in the other, suggesting that finan-
cial aid can positively impact OST retention rates [19].
Another USA study in which patients were providedwith incentive vouchers in order to increase program ad-
herence similarly showed increased retention rates [25].
Although there has been some research into the fac-
tors influencing OST program retention rates there has
been limited research covering OST patients’ finances
and the potential impact of dispensing fees on compli-
ance and retention in the OST program[19,26]. This
study aimed to obtain opinions and feedback from pa-
tients and stakeholders about the impact of dispensing
fees on patients’ debt, lifestyles and success or retention
in the OST program.
Methods
This study was conducted in Perth, Western Australia,
between June and August 2013. A mixed methodology
involving quantitative and qualitative data collection
strategies was used to obtain data from OST patients
and stakeholders. Three approaches were utilised namely
1) interviews with OST stakeholders, 2) a focus group of
OST patients and 3) surveys of OST patients. All infor-
mation and data collected were de-identified and partici-
pants’ identities remained confidential. Ethics approval
was obtained from the Curtin University Human Ethics
Committee (approval number PH-10-13).
Stakeholder and focus group interviews
A stakeholder interview guide was developed to gather
opinions and perspectives on how OST dispensing fees
potentially impacted on patients and whether there could
be a correlation between the fees and patient compliance
and retention in the program. The interview guide con-
sisted of 10 open-ended questions that covered:
 Whether time on OST correlated with ongoing
abstinence from opioids
 OST patient financial aspects: groups of patients
who struggle to pay dispensing fees (i.e. single
mothers, teenagers), pricing of take-away doses,
potential impact of dispensing fees on lifestyle
factors, accumulated dispensing fee debt and the
potential value of finance workshops to up-skill
patients
 Recommendations to improve or regulate the cost
of OST dispensing fees.
Stakeholders were purposively selected to ensure par-
ticipants were knowledgeable about OST medicine sup-
ply issues. All stakeholders approached were therefore in
regular contact with OST patients and in an ideal pos-
ition to provide feedback about the program. Potential
stakeholder participants were given an information sheet
about the study and asked to sign a consent form. Inter-
views were conducted face-to-face at a time and place
that was convenient for the participants.
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generate discussion with OST patients focusing on:
 The impact of dispensing fees on lifestyle and
retention and success with OST
 Potential value of finance and lifestyle workshops to
up-skill OST patients
 Recommendations to improve or regulate the cost
of OST dispensing fees
Focus group participants were purposively selected by
the Western Australia Substance Users Association
(WASUA) staff members to involve patients with vary-
ing opinions and experiences with the OST program.
All participants were given an information sheet about
the study and asked to sign a consent form. The focus
group was conducted at the WASUA offices.
The interviews and focus group were conducted by
members of the research team skilled in interview tech-
niques and the running of a focus group. All stakeholder
and focus group interviews were audio-recorded.Surveys
A survey consisting of eleven questions was developed to
collect some information about OST patients’ status (i.e.
relationships, employment and children), duration of OST
treatment, factors impacting on the success of treatment,
current income level and whether dispensing fees altered
their lifestyle or contributed to debt. The survey was de-
signed as a two-page survey as consultation with health
professionals involved with OST patients and WASUA
staff indicated that the survey had to be short to facilitate
participation. The surveys were distributed over a six week
period through:
 A specialist OST medical clinic located near the
Perth central business district (CBD) that provided
services to approximately 500 OST patients
 WASUA, and
 Two community pharmacies located north and
south of the Perth CBD. These pharmacies were two
of the largest OST dispensing pharmacies in Perth.
These locations were carefully selected to ensure a di-
verse range of OST patients were surveyed and to reduce
any bias towards particular patient demographics. Staff at
the various locations were briefed about the study and
provided with background information and instructions
about eligibility criteria, namely patients on OST at the
time of the study who were ≥ 18 years old. The staff made
the participant information sheets and surveys available to
eligible patients during patient visits, indicating that par-
ticipation in the survey was voluntary.Data analyses
Qualitative analyses: All stakeholder and focus group inter-
views were manually transcribed. Participants were de-
identified and codes were used in the analysis. Data analysis
was informed by the general inductive approach [27]: tran-
script content was read repeatedly by the research team to
attain a thorough understanding of topics that emerged
from the interviews. A colour-coding scheme was used to
identify themes. Topics and themes were developed to cap-
ture core messages reported by the participants. Emerged
ideas or themes were recorded and supporting quotes doc-
umented under each theme. To ensure reliability of the
process of analysis all authors reviewed the themes and
provided input throughout the data analysis process.
Quantitative analyses: The association between the two
primary outcome variables (debt and impact on lifestyle)
was assessed using the Chi-square statistic. Logistic re-
gression models were used to identify independent vari-
ables which were associated with each of these outcomes.
For each outcome, the independent variables included:
cost 1) considered to cause a significant impact, 2) cost
per fortnight (dispensing fee), and 3) demographic data:
single, employed, having dependent children, and time on
the OST program. The Likert scale responses (scores: 1 to
5) for the dependent variables were reduced by classifying
responses 1,2 as ‘low impact’, and 4,5 as causing significant
impact. The middle response indicating ‘sometimes im-
pact’, was excluded from analysis. For each outcome, a
‘backwards elimination’ method was used to reach the
optimum model. This method involves fitting all the inde-
pendent variables to the model initially, then dropping the
least significant variable (one at a time) until all variables
remaining in the model were significantly associated with
the outcome. Results of these regressions were presented
as odds ratios, their 95% confidence intervals, and p-
values. For all tests, a p-value < 0.05 was taken to indicate
a statistically significant association. Analyses were per-
formed using the SPSS version 21 statistical software.
Results
Stakeholder and focus group interviews
Stakeholder participants were:
 Three OST support workers (IP1, IP2 and IP3)
 A Community Program for Opioid
Pharmacotherapy (CPOP) administrator from the
Western Australian Health Department (IP4)
 A CPOP manager (IP5)
 A CPOP co-ordinator (IP6)
 A CPOP prescriber who treated large numbers of
OST patients (IP8)
 A community pharmacist manager from a pharmacy
that provided OST dispensing services to large
numbers of OST patients (IP7)
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nutes. The focus group of forty minutes involved four
OST patients that varied in age, gender, and time on the
OST program (between three and 20 years).
Four themes emerged from the stakeholder interviews
and focus group data. Emerged themes were recorded
and supporting quotes documented under each theme.
OST cost and patient drop-out rates
When stakeholder interview participants were asked to
comment on the most common factors causing patients
to prematurely drop out of the OST program, the majority
of stakeholders (5/8) declared cost as the factor mostly
impacting on OST compliance. Table 1 provides a sum-
mary of the drop-out factors with selected quotes.
The local prescriber (IP8) indicated that although factors
such as inflexible dosing requirements, discrimination at
the pharmacy and travelling restrictions made it difficult
for patients to participate in the program, these were not
likely to cause patient drop-out as arrangements could be
made to overcome most of these barriers. The prescriber
suggested that the cost of the dosing and patients’ inability
to pay for OST medicines were more likely to contribute
towards patient drop-out.
The results obtained from the focus group supported
the stakeholder opinions with cost, relapse and inflexibility
of the program raised as common factors causing patients
drop-outs.
OST fees impact on patient lifestyle factors
Stakeholder interview participants were asked how pa-
tients’ lifestyles were potentially impacted by having toTable 1 Interview data of the factors influencing patient drop
support themes
Themes Selected quotes
Financial burden “All of the money before was coming fro
patients come on methadone they usual
debt to drug dealer, debt to family/friend
Relapse “…patients may not be able to go to the
week they won’t be able to afford their do
left with the option of sitting at home and
Lack of support “ …people are put on the program witho
thing” (IP2)
Insufficient take-away doses - eg.
mine workers
“I think that patients should be able to g
Pharmacy discrimination “They are treated differently to the other
Limiting daily life “… can be debilitating to be on the prog
of my position I could have not held tha
“liquid handcuffs” (IP2)
Inadequate preparation The length of the program … “may no
that moment” (IP1).
“knee jerk reaction – thinking CPOP is go
Rural location “If someone gets a job up north- may nopay the OST dispensing fees. All participants commen-
ted that most, if not all patients entering the OST pro-
gram, would have financial debt and be at the lowest
point in their life. It was also highlighted that many pa-
tients were not able to engage in a healthy social life
such as participating in activities like going to the
movies, doing exercise and fitness classes or going out
for dinner or coffee with friends, family or partners.
Another recurring topic was that patients accumulate
debt to pharmacies:
“… pharmacies generally allow patients to book up
their cost of dosing and then the manager/owner of the
store will eventually just cut them off. This can be
done at times with no warning …” (IP3).
However, one of the participants (IP7), a pharmacist,
commented that 85% of their patients were up-to-date
or in advance on their dosing fees. This pharmacy dosed
approximately 160 patients and was one of the largest
OST dispensing pharmacies in the metropolitan area at
the time of the study.
Stakeholder interview participants were asked if they
were able to identify any particular demographic groups
that were impacted by dispensing fees. A number of dif-
ferent groups were identified, and these included: pa-
tients newly released from prison, patients with other
medical conditions and expenses, pensioners and the
unemployed. The overall consensus was that the major-
ity of patients on the OST program would classify into
one of these groups. It was also proposed that the gen-
eral characteristic of being a previous addict meant that-outs from OST program with selected quotes to
m crime and they were able to pay hundreds of dollars for heroin. When
ly don’t have a lot of resources… all would be in debt… credit card debt,
s, and ordinary sorts of debt”. (IP8)
movies or take partner out for dinner because that would mean that next
se… bored sitting at home, not able to go out to gym or yoga or movies…
watching TV. This leads to relapse because they have nothing else to do”. (IP1)
ut sufficient support and go on without being aware that it is a long term
et more take away doses… be able to self-manage” (IP1)
customers. It happens all the time” (IP3).
ram… I travel interstate a lot for work- if the organisation was not aware
t position down” (IP2)
t be entirely understood by the consumer as it may be less important in
ing to be the silver bullet for all their problems” (IP2).
t take the job due to not being able to dose up there” (IP7)
Shepherd et al. Substance Abuse Treatment, Prevention, and Policy 2014, 9:32 Page 5 of 9
http://www.substanceabusepolicy.com/content/9/1/32patients’ priorities did not always align with paying fees
on time.
The focus group participants identified that being on
the OST program impacted significantly on everyday life.
For example patients are not able to afford to go on hol-
idays or have a normal social life.
Time on OST program and continued opioid abstinence
Stakeholder interview participants were asked to com-
ment on the correlation between time on OST program
and patient stability, either when on or off the program.
Seven out of the eight interview participants commented
that there was a positive correlation between the two,
namely the longer a patient stays on the program the
better the outcome. Two of the interview participants
commented that the stability of a patient is dependent
on the individual patient’s situation and support network
and that it is therefore difficult to suggest an estimated
length of therapy for a patient when commencing with
the program. However it was estimated by most partici-
pants that the majority of patients would need between
six and twelve months on the program to change other
facets of their life in order to become stable:
“… six months onwards – can take up to 1-2 years to
really get their life back together… employment, fixing
their relationships with family and friends, forming new
relationships with people outside the drug world…” (IP8).
Patient support
Stakeholder interview participants were asked to make
suggestions as to what may potentially support patients
to better manage their OST fees. Most stakeholders ad-
vocated for OST fees to contribute towards the Pharma-
ceutical Benefits Scheme Safety Net (6/8), and for fee
subsidy (5/8). The rationale used by six out of eight par-
ticipants was that drug addiction should be recognised
as a medical condition as is the case with the other con-
ditions covered under the Safety Net Scheme:
“…it is a medical condition. The PBS covers smoking
drugs… they are the same concept apart from one drug
being legal and the other not …” (IP7).Table 2 Survey data of the impact of dispensing fees on lifes
No impact (%)
Debt groups (%) Never in debt 48.1
Sometimes in debt 11.6
Always in debt 2.9
Total (%) 24
Note: Numbers in the cells are the percentages of responses within the rows of the
Chi-square analysis performed for cross tabulation, p-value <0.001. This illustrates aOther suggestions made were to have a fixed dispens-
ing fee, provide budgeting workshops, allowing patients
to skip doses to save money, attend mandatory counsel-
ling, offer reimbursements, provide a resource book on
where to seek help, and subsidise patients coming out of
prison. It was raised by three of the eight interview par-
ticipants that it was important not to increase barriers to
participate in the program:
“… the program has to have a degree of flexibility …” (IP7).
All four focus group members supported the idea of
having the PBS Safety Net Scheme apply to OST dis-
pensing fees. The group also expressed the need to have
a free dosing clinic that was more readily available for
patients that were in need of more financial support.
Survey results
A total of 138 surveys were completed. Participants
included 76 males and 62 females with ages between
21 and 61 years (mean [standard deviation] = 40.0 [9.4]).
The data showed a high rate of unemployment (36.1%)
amongst the participants with a large portion (52.2%) of
the participants being on a low income of less than $500
per fortnight.
Dispensing fees and their impact on debt and lifestyle
A cross tabulation was completed to show the percentage
of participants who experienced significant impact on life-
style when in debt due to dispensing fees. Questions 10
and 11 requested information concerning the impact of
cost of dispensing fees on lifestyle and whether the fees
caused participants to incur any debt. The Chi-square test
(Table 2) indicates that there is a strong correlation be-
tween debt and impacted lifestyle. Of the participants who
were always in debt, the majority also indicated that dis-
pensing fees significantly impacted their lifestyle, while the
percentage was significantly lower for those not always in
debt (p < 0.001, χ2 = 45.3, df = 4).
Factors impacting on the success in the OST program
Survey participants were presented with six factors af-
fecting the success of their OST, and asked to rank themtyle and debt of OST patients
Lifestyle groups






positive correlation between debt and lifestyle impacts from patient surveys.
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the least impact (scored as 6). The factors were:
 Travel
 Dosing times
 The cost of dispensing fees
 Not having enough take-away doses
 Feeling judged
 Limited dosing venues
Figure 1 shows the distribution (numbers of responses)
of the factors considered to have the greatest impact on
success of the OST. Cost was clearly impacting on therapy
as 64 participants (46.4%) ranked it as the factor most
likely to influence their retention in the OST program.
Logistic regression models were used to determine if any
of the independent variables (cost impact, cost of therapy,
relationship status, having children, employment status and
the time spent in the OST program) influenced being in
debt or having lifestyle difficulties. Table 3 summarises the
results of these analyses, and shows that ‘Cost Impact’ sig-
nificantly influenced both the occurrence of debt (57.7% vs
11.4%, p < 0.0001) and lifestyle difficulties (80.0% vs 33.3%,
p = 0.0004). In addition, being in employment significantly
(p = 0.0308) raised the odds of lifestyle difficulties (com-
pared with those respondents not in employment). For
these analyses, “Cost impact” was a binary variable (Yes/
No) defined as “Yes” if cost was classified as either the most
important or second most important factor affecting suc-
cess of the OST program (ranked 1 or 2). These associa-
tions show that participants who identified that cost
affected their success in the OST program were significantly
more likely to incur debt and have lifestyle difficulties.
Discussion
This study obtained opinions and feedback from patients
and stakeholders about the impact of dispensing fees onFigure 1 Survey data of factors impacting on OST patients’ success inpatients’ debt, lifestyles and success or retention in the
OST program. The stakeholders and OST patients both
identified OST out-of-pocket dispensing fees as the main
factor associated with OST non-compliance and early
drop-out from the OST program. The survey data
showed that dispensing fees impacted patients’ treat-
ment in several ways including treatment compliance,
debt accumulation and impact on lifestyle. All of these
factors may increase the chance of a patient leaving the
program. OST cost indeed received the highest rating in
influencing retention in the OST program and there was
a positive correlation between time on the OST program
and success in terms of relapse prevention.
Treating a person with heroin or another opioid addic-
tion is complex and the treatment process is multifaceted,
requiring a holistic approach [28]. Seeking abstinence may
not be the immediate goal but rather seeking normality
and stability in the patient’s life [9,12]. The length of time
a patient spends on OST is positively correlated with ther-
apy success [19]. The first 12 months in OST is important
as patients are at high risk of relapsing, are often finan-
cially unstable and vulnerable. It is therefore important to
keep patients in the program during this initial stage. Re-
tainment in the program in the initial phase of OST tends
to increase the patient’s chance of obtaining long-term sta-
bility and abstinence from the addicted drug [26]. Patients
often need to work on repairing relationships, treating
other health issues (HIV [5,8], malnutrition [29], and men-
tal health disorders [30]), and gain financial stability via a
regular income source [22,28,31]. In order for patients to
achieve these goals they require OST to treat the physical
withdrawal symptoms caused by ceasing the use of the
abused drug.
The findings from this study suggest that treatment is
impacted negatively by out-of-pocket OST dispensing
fees as patients often encounter financial pressures. As
the study sample seems to be representative of the widerthe program (n = 138).
Table 3 Survey data factors influencing impact on debt and lifestyle: logistic regression analyses of these two
dependent variables
Dependent variable Independent variable Number n/N (%)* Odds ratio 95% Confidence interval p-value
Being in debt Cost impact
No 4/35 (11.4) 1 (reference)
Yes 30/52 (57.7) 10.6 3.3 to 34.3 <0.0001
Lifestyle difficulties Cost impact
No 10/30 (33.3) 1 (reference)
Yes 48/60 (80.0) 6.6 2.3 to 18.9 0.0004
Employed
No 8/22 (36.4) 1 (reference)
Yes 46/63 (73.0) 3.5 1.1 to 10.9 0.0308
*n/N shows the number of cases with a ‘significant impact’ response for each outcome, out of the total number in the row.
Logistic regression models used.
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should be similar for other OST patients in this state.
This study also highlighted a number of reasons why a
patient may drop out of an OST program, with the main
reason being the cost of the dispensing fee. Previous
studies indicated that financial incentives and rewards
increase patient compliance [23,25,32]. This highlights
the importance of financial assistance to improve patient
retention rates in OST programs.
Survey data showed that OST patients’ lifestyles were
impacted by the cost of the dispensing fees. Additionally,
there was a correlation between participants who indi-
cated that the fees impacted on their lifestyle and the ac-
cumulation of high personal debt. These findings show
that the current charging practices of OST dispensing
fees not only increase drop-out rates due to an increase
in the relapse risk [33-35] and the inability to pay for
doses, but also increase the risk of adverse health prob-
lems. Financial pressure from personal debt has been
linked to an increased risk of substance abuse [36], men-
tal health issues, depression, suicidal ideation, stress, and
anxiety [36-38]. The prevalence of these health issues
are high in drug addiction patients [39] and the added fi-
nancial pressure from the dispensing fees are likely to
exacerbate these conditions.
The World Health Organisation (WHO) states that
healthcare systems should aim to provide equitable
healthcare to all people. WHO defines health equity as
“the absence of unfair and avoidable or remediable dif-
ferences in health services and outcomes among groups of
people” [40]. In 2000 WHO identified three areas of
focus namely “health, responsiveness and financing fair-
ness” [41]. Patients in OST programmes need to pay
regular dispensing fees and they hence have extra health
expenses. Although the PBS provides for the medicine
itself to be entirely subsidised by the government, the
fee associated with the dispensing of the medicine is not
regulated and there is no financial assistance for this feein Western Australia. Participants were of the opinion
that OST dispensing fees should contribute towards the
PBS Safety Net Scheme as is the case with patients who
suffer from chronic conditions. Considering the current
dispensing fees, Western Australian OST patients who
obtain their OST medicines at community pharmacies
pay on average $154 per month for their dosing, which
is significantly more compared to patients paying for
medicines for diabetes, smoking, and hypercholesterol-
emia. Although these conditions could also be the result
of lifestyle choices, the dispensing of the medicines to
treat these conditions contributes towards a patient’s
Safety Net, which is not the case with OST medicines.
Opioid dependence is therefore not considered at the
same level as other medical conditions and OST patients
are financially disadvantaged under the current PBS
arrangements.
Interview participants indicated that patients are often
in debt to pharmacies as a result of their inability to pay
the dispensing fees. Pharmacy staff therefore need to
follow-up with patients to recover the debt which adds
to perceptions of stigma from staff as well as self-stigma
by patients. It could be argued that pharmacists might
be able to dose more patients and more pharmacies
might be willing to participate in the OST program
should the government sponsor the dispensing fees.
This study was limited by the small number of venues
surveyed. In addition, the surveys relied on the accuracy
of self-reported data. However, this method was deemed
appropriate to obtain data from this vulnerable popula-
tion. The study only involved OST patients within the
Perth metropolitan area and therefore lacks country and
rural patients’ perspectives. Furthermore, the study was
conducted in Australia and the findings may not apply
to settings outside Australia. Purposive sampling was
used to locate key stakeholders, possibly limiting the
generalisability of the interview findings. However, pur-
posive sampling was deemed the most appropriate
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the topic of discussion. The interview method can be
subject to interview bias, and participants may lean to-
wards responses which have greater social desirability.
However, the potential for interviewer bias was mini-
mised with the use of a standardised interview frame-
work. Finally, this study was time-limited and conducted
over a relatively short timeframe which reduced the
scope of the study.
Conclusion
This study provided insight into OST patients’ financial
difficulties and the data suggest that out-of-pocket dis-
pensing fees are likely to have a negative impact on
Western Australian OST patients’ compliance with ther-
apy, retention in the OST program and lifestyle. Govern-
ment sponsorship of the OST dispensing fees should be
considered as sponsorship would potentially increase the
retention rates of income-poor OST program recipients.
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